Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross‐sectional study

Abstract

Abstract. Shore AC, Colhoun HM, Natali A, Palombo

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

“…[16][17][18][19] In accordance, subjects with T2DM were found to have increased pulse wave velocity and a lower reactive hyperaemia index at the SUMMIT VIP baseline investigation. 12 In spite of this, neither of these measures predicted the occurrence of a new event in subjects with established CVD in the present study.…”

“…The clinical characteristics of the study cohort have been previously published. 12 Fatal and non-fatal cardiovascular (CV) events were registered during a 3-year follow-up period. Seventy-seven subjects (5.1%) were excluded from the study due to lack of information of clinical events during follow-up.…”

“…20 In accordance, T2DM subjects with manifest CVD at the baseline investigation had significantly greater carotid IMT than those without manifest CVD. 12 Hence, there seems to be a clear association between atherosclerosis severity and CV risk in subjects with T2DM, but this association diminishes in subjects with manifest CVD.…”

Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes

“…A more detailed description of this cohort, including differences in vascular changes between the different groups, has recently been published. 12 The plasma levels of all MMPs except MMP-1 demonstrated significant covariation (Table I in the online-only Data Supplement). The highest degree of covariation was seen between MMP-7 and -12 (r=0.54, P=6.3E-109).…”

Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes

“…The SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) study cohort consisted of 4 groups; (1) subjects with T2D and clinically manifest CVD, (2) subjects with T2D but without clinical signs of CVD, (3) subjects with CVD but no diabetes and (4) subjects without both CVD and diabetes recruited from existing population cohorts and hospital registers at the university hospitals in Malmö (Sweden), Pisa (Italy), Dundee and Exeter (UK) between December 2010 and April 2013 [17]. Diabetes was defined by current or previous evidence of hyperglycemia (according to WHO 1998 criteria; fasting plasma glucose >7.0 mmol/l or 2-h plasma glucose >11.1 mmol/l, or both) or by current medication with insulin, sulphonylureas, metformin or other anti-diabetic drugs.…”